A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)
This study is testing a new experimental pill called TYRA-200 to see if it can safely and effectively treat advanced bile duct cancers and other solid tumors. It is specifically designed for patients whose tumors have a particular gene change known as an FGFR2 alteration.
This trial is for adults 18 and older with advanced solid tumors that have specific gene changes where standard treatments haven't worked or aren't an option. You must also be able to maintain your daily activities, and your doctor will need to confirm you don't have certain pre-existing heart, eye, or liver conditions.
Participants will take the study drug, TYRA-200, as a daily pill in 28-day cycles. Doctors will monitor you closely throughout the study to track how your tumor responds to the medication and to manage any potential side effects.
The study is currently recruiting patients at medical centers in San Francisco, Boston, and Columbus. You can talk to your doctor or reach out to these locations to learn more about joining.
- 1This is a first-in-human study, meaning it is the first time this medication is being tested in people.
- 2The treatment is a simple daily pill taken at home.
- 3Participants must have specific genetic markers in their tumor to be eligible.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.